AstraZeneca LP v. InvaGen Pharmaceuticals Inc.

Application Number	Patent Number	External Links
-	US6251910	Espacenet Google Patents
-	US6525060	Espacenet Google Patents
-	US7250419	Espacenet Google Patents
-	US7265124	Espacenet Google Patents
-	US8425934	Espacenet Google Patents

COMPLAINT filed against InvaGen Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 1818751.) - filed by AstraZeneca LP, AstraZeneca UK Limited, AstraZeneca Pharmaceuticals LP, AstraZeneca AB. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Civil Cover Sheet)(cna) (Entered: 11/02/2015)

2015-10-30

1

Download

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cna) (Entered: 11/02/2015)

2015-10-30

1

View

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 9/19/2015. Date of Expiration of Patent: 7/15/2015; 12/2/2019; 7/9/2015; 6/17/2030.Thirty Month Stay Deadline: 1/20/2019. (cna) (Entered: 11/02/2015)

2015-10-30

1

View

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; 6,525,060; 7,250,419; 7,265,124; 8,425,934. (cna) (Entered: 11/02/2015)

2015-10-30

1

Download

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca LP filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (cna) (Entered: 11/02/2015)

2015-10-30

1

View

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca AB filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (cna) (Entered: 11/02/2015)

2015-10-30

1

View

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca Pharmaceuticals LP filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (cna) (Entered: 11/02/2015)

2015-10-30

1

View

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca UK Limited filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (cna) (Entered: 11/02/2015)

2015-10-30

1

View

Summons Issued

2015-11-02

1

No Actions

Case Assigned/Reassigned

2015-11-04

1

No Actions

DECLARATION of Mailing regarding service on Invagen Pharmaceuticals Inc. made on November 2, 2015, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Attachments: # 1 Exhibits A-B)(Smyth, Benjamin) Modified on 11/9/2015 (nms). (Entered: 11/09/2015)

2015-11-09

1

View

STIPULATION TO EXTEND TIME to Answer Complaint to December 14, 2015 - filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) (Entered: 11/12/2015)

2015-11-12

1

View

~Util - Set/Reset Answer Deadline AND SO ORDERED

2015-11-12

1

No Actions

NOTICE of Appearance by R. Touhey Myer on behalf of InvaGen Pharmaceuticals Inc. (Myer, R.) (Entered: 11/24/2015)

2015-11-24

1

View

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by InvaGen Pharmaceuticals Inc.. (Myer, R.) (Entered: 11/24/2015)

2015-11-24

1

View

MOTION for Pro Hac Vice Appearance of Attorney Robert Silver - filed by InvaGen Pharmaceuticals Inc.. (Attachments: # 1 Certification of Robert Silver)(Myer, R.) (Entered: 11/24/2015)

2015-11-24

1

View

MOTION for Pro Hac Vice Appearance of Attorney Pei-Ru Wey - filed by InvaGen Pharmaceuticals Inc.. (Attachments: # 1 Certification of Pei-Ru Wey)(Myer, R.) (Entered: 11/24/2015)

2015-11-24

1

View

MOTION for Pro Hac Vice Appearance of Attorney Salvarotre Guerriero - filed by InvaGen Pharmaceuticals Inc.. (Attachments: # 1 Certification of Salvatore Guerriero)(Myer, R.) (Entered: 11/24/2015)

2015-11-24

1

View

SO ORDERED

2015-11-24

1

No Actions

MOTION for Pro Hac Vice Appearance of Attorney Mark J. Feldstein, Charles E. Lipsey, Ryan P. O'Quinn and Jill K. MacAlpine - filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Attachments: # 1 Certification for Mark J. Feldstein, Charles E. Lipsey, Ryan P. O'Quinn and Jill K. MacAlpine)(Silver, Daniel) (Entered: 12/07/2015)

2015-12-07

1

View

MOTION for Pro Hac Vice Appearance of Attorney Mark J. Feldstein, Charles E. Lipsey, Ryan P. O'Quinn and Jill K. MacAlpine - filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Attachments: # 1 Certification for Mark J. Feldstein, Charles E. Lipsey, Ryan P. O'Quinn and Jill K. MacAlpine)(Silver, Daniel) (Entered: 12/07/2015)

2015-12-07

1

View

SO ORDERED

2015-12-08

1

No Actions

ANSWER to 1 Complaint, COUNTERCLAIMS against all Plaintiffs, by InvaGen Pharmaceuticals Inc..(Myer, R.) Modified on 12/14/2015 (nms). (Entered: 12/14/2015)

2015-12-14

1

View

Add Attorneys - PHV only

2015-12-14

1

No Actions

Add Attorneys - PHV only

2015-12-15

1

No Actions

STIPULATION And Proposed Order of Dismissal of Plaintiffs Count I and Defendants Counterclaim Count I, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) Modified on 1/5/2016 (nms). (Entered: 01/04/2016)

2016-01-04

1

View

ORDER re 18 Stipulation and Proposed Order of Dismissal of Plaintiffs' Count I and Defendant's Counterclaim Count I. Signed by Judge Richard G. Andrews on 1/5/2016. (nms) (Entered: 01/05/2016)

2016-01-05

1

View

ANSWER to 17 Answer to Complaint, Counterclaim by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited.(Silver, Daniel) (Entered: 01/07/2016)

2016-01-07

1

View

Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 2/10/2016, at 2:30 PM in Courtroom 6A before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 2/10/2016. (nms) (Entered: 01/19/2016)

2016-01-19

1

View

Proposed Scheduling Order, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) Modified on 2/9/2016 (nms). (Entered: 02/08/2016)

2016-02-08

1

View

Proposed Scheduling Order, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) Modified on 2/9/2016 (nms). (Entered: 02/08/2016)

2016-02-08

1

View

Scheduling Conference

2016-02-10

1

No Actions

Official Transcript of Scheduling Conference held on 02-10-16 before Judge Richard G. Andrews. Court Reporter/Transcriber Leonard A. Dibbs. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 3/3/2016. Redacted Transcript Deadline set for 3/14/2016. Release of Transcript Restriction set for 5/11/2016. (lad) (Entered: 02/11/2016)

2016-02-11

1

View

Official Transcript of Scheduling Conference held on 02-10-16 before Judge Richard G. Andrews. Court Reporter/Transcriber Leonard A. Dibbs. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 3/3/2016. Redacted Transcript Deadline set for 3/14/2016. Release of Transcript Restriction set for 5/11/2016. (lad) (Entered: 02/11/2016)

2016-02-11

1

View

MOTION for Pro Hac Vice Appearance of Attorney Lynn M. Terrebonne - filed by InvaGen Pharmaceuticals Inc.. (Attachments: # 1 Certification of Lynn M. Terrebonne)(Myer, R.) (Entered: 02/23/2016)

2016-02-23

1

View

SO ORDERED

2016-02-24

1

No Actions

PROPOSED Scheduling Order, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) Modified on 2/25/2016 (nms). (Entered: 02/25/2016)

2016-02-25

1

View

PROPOSED Scheduling Order, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) Modified on 2/25/2016 (nms). (Entered: 02/25/2016)

2016-02-25

1

View

SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. The above-captioned actions are hereby consolidated for all discovery and validity trial, but not for infringement trials, into C.A. No. 15-1000-RGA. From this point forward, all filings pertaining to any of the above-captioned actions shall be filed on the docket in C.A. No. 15-1000-RGA. Joinder of Parties due by 12/31/2016. Amended Pleadings due by 12/31/2016. Fact Discovery completed by 6/8/2017. Joint Claim Construction Opening Brief due by 1/25/2017. A Markman Hearing is set for 2/14/2017, at 8:30 AM in Courtroom 6A before Judge Richard G. Andrews. A Pretrial Conference is set for 3/16/2018, at 8:30 AM in Courtroom 6A before Judge Richard G. Andrews. A 3 day Bench Trial on validity issues is set for 3/26/2018, at 8:30 AM in Courtroom 6A before Judge Richard G. Andrews. One day Bench Trials are set for 4/2/2018, at 8:30 AM in Courtroom 6A; 4/4/2018, at 8:30 AM in Courtroom 6A; 4/6/2018, at 8:30 AM in Courtroom 6A; 4/9/2018, at 8:30 AM in Courtroom 6B; 4/11/2018, at 8:30 AM in Courtroom 6A; 4/13/2018, at 8:30 AM in Courtroom 6A; 4/16/2018, at 8:30 AM in Courtroom 6A; 4/18/2018, at 8:30 AM in Courtroom 6A; 4/20/2018, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 2/25/2016. Associated Cases: 1:15-cv-00999-RGA et al.(nms) (Entered: 02/25/2016)

2016-02-25

1

View

SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. The above-captioned actions are hereby consolidated for all discovery and validity trial, but not for infringement trials, into C.A. No. 15-1000-RGA. From this point forward, all filings pertaining to any of the above-captioned actions shall be filed on the docket in C.A. No. 15-1000-RGA. Joinder of Parties due by 12/31/2016. Amended Pleadings due by 12/31/2016. Fact Discovery completed by 6/8/2017. Joint Claim Construction Opening Brief due by 1/25/2017. A Markman Hearing is set for 2/14/2017, at 8:30 AM in Courtroom 6A before Judge Richard G. Andrews. A Pretrial Conference is set for 3/16/2018, at 8:30 AM in Courtroom 6A before Judge Richard G. Andrews. A 3 day Bench Trial on validity issues is set for 3/26/2018, at 8:30 AM in Courtroom 6A before Judge Richard G. Andrews. One day Bench Trials are set for 4/2/2018, at 8:30 AM in Courtroom 6A; 4/4/2018, at 8:30 AM in Courtroom 6A; 4/6/2018, at 8:30 AM in Courtroom 6A; 4/9/2018, at 8:30 AM in Courtroom 6B; 4/11/2018, at 8:30 AM in Courtroom 6A; 4/13/2018, at 8:30 AM in Courtroom 6A; 4/16/2018, at 8:30 AM in Courtroom 6A; 4/18/2018, at 8:30 AM in Courtroom 6A; 4/20/2018, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 2/25/2016. Associated Cases: 1:15-cv-00999-RGA et al.(nms) (Entered: 02/25/2016)

2016-02-25

1

View

ORAL ORDER: On or before March 10, 2016, each party or each party group shall email to Chief Magistrate Judge Thynge, with a copy to her Judicial Administrator, Cathleen Kennedy, the information requested in the attached Order. Ordered by Judge Thynge on 2/25/16. (Attachments: # 1 Order Requesting Information re: ADR) Associated Cases: 1:15-cv-00999-RGA et al.(cak) (Entered: 02/25/2016)

2016-02-25

1

View

ORAL ORDER: On or before March 10, 2016, each party or each party group shall email to Chief Magistrate Judge Thynge, with a copy to her Judicial Administrator, Cathleen Kennedy, the information requested in the attached Order. Ordered by Judge Thynge on 2/25/16. (Attachments: # 1 Order Requesting Information re: ADR) Associated Cases: 1:15-cv-00999-RGA et al.(cak) (Entered: 02/25/2016)

2016-02-25

1

View

Pro Hac Vice Attorney Lynne Terrebonne for InvaGen Pharmaceuticals Inc., and Sigmapharm Laboratories, LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. Associated Cases: 1:15-cv-01001-RGA, 1:15-cv-01000-RGA(klc)

2016-02-25

1

No Actions

CASE REFERRED to Chief Magistrate Judge Thynge for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at http://www.ded.uscourts.gov/general-orders/magistrate-judges-standing-order-adr-mediation Associated Cases: 1:15-cv-00999-RGA et al.(cak)

2016-02-25

1

No Actions

Case Referred to Mediation - Magistrate Judge only

2016-02-25

1

No Actions

Add Attorneys - PHV only

2016-02-25

1

No Actions

CASE CLOSED per D.I. 446 in Lead Civil Action 15-1000-RGA. (nms)

2018-03-09

1

No Actions

Terminate Case - Civil

2018-03-09

1

No Actions

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; 6,525,060; 7,250,419; 7,265,124; 8,425,934. (Attachments: # 1 Consent Judgment)(nms) (Entered: 03/15/2018)

2018-03-15

1

View

Overview

Parties

Movant

AstraZeneca Pharmaceuticals LP Follow

Represented By

Defendant

InvaGen Pharmaceuticals Inc. Follow

Represented By

AstraZeneca AB Follow

Represented By

AstraZeneca LP Follow

Represented By

Plaintiff

AstraZeneca UK Limited Follow

Represented By

Court & Judges

Patents Involved

Docket Entries

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (cna) (Entered: 11/02/2015)

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 9/19/2015. Date of Expiration of Patent: 7/15/2015; 12/2/2019; 7/9/2015; 6/17/2030.Thirty Month Stay Deadline: 1/20/2019. (cna) (Entered: 11/02/2015)

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; 6,525,060; 7,250,419; 7,265,124; 8,425,934. (cna) (Entered: 11/02/2015)

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca LP filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (cna) (Entered: 11/02/2015)

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca AB filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (cna) (Entered: 11/02/2015)

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca Pharmaceuticals LP filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (cna) (Entered: 11/02/2015)

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent AstraZeneca PLC for AstraZeneca UK Limited filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (cna) (Entered: 11/02/2015)

Summons Issued

Case Assigned/Reassigned

DECLARATION of Mailing regarding service on Invagen Pharmaceuticals Inc. made on November 2, 2015, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Attachments: # 1 Exhibits A-B)(Smyth, Benjamin) Modified on 11/9/2015 (nms). (Entered: 11/09/2015)

STIPULATION TO EXTEND TIME to Answer Complaint to December 14, 2015 - filed by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) (Entered: 11/12/2015)

~Util - Set/Reset Answer Deadline AND SO ORDERED

NOTICE of Appearance by R. Touhey Myer on behalf of InvaGen Pharmaceuticals Inc. (Myer, R.) (Entered: 11/24/2015)

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by InvaGen Pharmaceuticals Inc.. (Myer, R.) (Entered: 11/24/2015)

MOTION for Pro Hac Vice Appearance of Attorney Robert Silver - filed by InvaGen Pharmaceuticals Inc.. (Attachments: # 1 Certification of Robert Silver)(Myer, R.) (Entered: 11/24/2015)

MOTION for Pro Hac Vice Appearance of Attorney Pei-Ru Wey - filed by InvaGen Pharmaceuticals Inc.. (Attachments: # 1 Certification of Pei-Ru Wey)(Myer, R.) (Entered: 11/24/2015)

MOTION for Pro Hac Vice Appearance of Attorney Salvarotre Guerriero - filed by InvaGen Pharmaceuticals Inc.. (Attachments: # 1 Certification of Salvatore Guerriero)(Myer, R.) (Entered: 11/24/2015)

SO ORDERED

SO ORDERED

ANSWER to 1 Complaint, COUNTERCLAIMS against all Plaintiffs, by InvaGen Pharmaceuticals Inc..(Myer, R.) Modified on 12/14/2015 (nms). (Entered: 12/14/2015)

Add Attorneys - PHV only

Add Attorneys - PHV only

STIPULATION And Proposed Order of Dismissal of Plaintiffs Count I and Defendants Counterclaim Count I, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) Modified on 1/5/2016 (nms). (Entered: 01/04/2016)

ORDER re 18 Stipulation and Proposed Order of Dismissal of Plaintiffs' Count I and Defendant's Counterclaim Count I. Signed by Judge Richard G. Andrews on 1/5/2016. (nms) (Entered: 01/05/2016)

ANSWER to 17 Answer to Complaint, Counterclaim by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited.(Silver, Daniel) (Entered: 01/07/2016)

Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 2/10/2016, at 2:30 PM in Courtroom 6A before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 2/10/2016. (nms) (Entered: 01/19/2016)

Proposed Scheduling Order, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) Modified on 2/9/2016 (nms). (Entered: 02/08/2016)

Proposed Scheduling Order, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) Modified on 2/9/2016 (nms). (Entered: 02/08/2016)

Scheduling Conference

MOTION for Pro Hac Vice Appearance of Attorney Lynn M. Terrebonne - filed by InvaGen Pharmaceuticals Inc.. (Attachments: # 1 Certification of Lynn M. Terrebonne)(Myer, R.) (Entered: 02/23/2016)

SO ORDERED

PROPOSED Scheduling Order, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) Modified on 2/25/2016 (nms). (Entered: 02/25/2016)

PROPOSED Scheduling Order, by AstraZeneca AB, AstraZeneca LP, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Limited. (Silver, Daniel) Modified on 2/25/2016 (nms). (Entered: 02/25/2016)

Case Referred to Mediation - Magistrate Judge only

Add Attorneys - PHV only

CASE CLOSED per D.I. 446 in Lead Civil Action 15-1000-RGA. (nms)

Terminate Case - Civil

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,251,910; 6,525,060; 7,250,419; 7,265,124; 8,425,934. (Attachments: # 1 Consent Judgment)(nms) (Entered: 03/15/2018)

Track Case Updates

AstraZeneca Pharmaceuticals LP

InvaGen Pharmaceuticals Inc.

AstraZeneca AB

AstraZeneca LP

AstraZeneca UK Limited